Cargando…
Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma
Treatment of malignant tumors, such as rhabdomyosarcoma (RMS), can improve overall survival (OS). It is time-consuming and expensive for patients to obtain benefits from randomized controlled trials (RCTs) with OS as the primary end-point. Therefore, another surrogate end-point is necessary; however...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653385/ https://www.ncbi.nlm.nih.gov/pubmed/36371419 http://dx.doi.org/10.1038/s41598-022-23944-w |